UBE2C Antibody

1. UBE2C is involved in the anti-proliferative and pro-apoptotic functions of ECRG4 in esophageal squamous cell carcinoma. PMID: 29268240
2. loss of BRCA1 function results in an increase in UBE2C expression and chemical resistance to doxorubicin in breast cancer cells. PMID: 28881292
3. FoxM1 promotes glioma progression by enhancing UBE2C transcription PMID: 28767320
4. SAG/RBX2 E3 ligase complexes with UBCH10 and UBE2S ubiquitin-conjugating enzymes to ubiquitylate beta-TrCP1 via K11-linkage for degradation. PMID: 27910872
5. UBE2C and HOXA1 RNA and protein are differentially expressed in conventional and Spitz nevi and melanoma. PMID: 28657121
6. High UBE2C expression is associated with esophageal squamous cell carcinoma. PMID: 27588470
7. Urinary UBE2C cell-free RNA may be a valuable diagnostic marker for bladder cancer. PMID: 27528424
8. A role was identified for UBE2C as a marker of the androgen signaling pathway in prostate cancer. PMID: 27550197
9. Data suggest that the activity of AURKA might be regulated by UBE2C through regulating the activity of anaphasepromoting complex. UBE2C may be a new marker in the diagnosis of gastric cancer and may be a potential therapeutic target for the treatment of gastric adenocarcinoma. PMID: 28260026
10. High UBCH10 expression is associated with bortezomib-resistance in multiple myeloma. PMID: 28000886
11. the expression of UbcH10 in colorectal cancer samples as compared with healthy tissue sample from the same patient according to age at surgery, was examined. PMID: 26744065
12. UbcH10 may promote gastric cancer growth. PMID: 27349176
13. Identification of UBE2C as a target of wild-type and GOF mutant p53 further highlights the contribution of p53 in regulation of spindle assembly checkpoint PMID: 27129209
14. The anaphase-promoting complex/cyclosome C activity in human cells is tuned by the combinatorial use of three E2 ubiquitin-conjugating enzymes, namely UBE2C, UBE2S, and UBE2D. PMID: 26904940
15. Study shows an overexpression of UbcH10 mRNA and protein in the vast majority of colorectal cancer (CRC) patients analyzed and indicates that UbcH10 expression regulates CRC growth. PMID: 25917796
16. the present study showed that miR-196a promoted cell proliferation by targeting UBE2C in breast cancer. Thus, miR-196a may be a potential oncogene in breast cancer and a promising therapeutic target in breast cancer treatment. PMID: 26062455
17. UBE2C could regulate phospho-ERK1/2 level. PMID: 25832867
18. Data suggest that ubiquitin-conjugating enzyme UbcH10 may be a promising target for the therapy of breast cancer. PMID: 25739083
19. Upregulation of miR-17/20a promotes gastric cancer cell growth by targeting UBE2C. PMID: 25760688
20. UbcH10 overexpression increases carcinogenesis and blocks ALLN susceptibility in colorectal cancer. PMID: 25376843
21. in addition to binding APC11's RING, UBCH10 is corecruited via interactions with APC2 PMID: 25825779
22. excess E2F1 due to Rb inactivation recruits the complex of Cdc20 and the anaphase-promoting complex/cyclosome to deregulate the expression of UBCH10 PMID: 25368385
23. UBE2C may be a marker for diagnosis of nonpalpable breast lesions but not benign or malignant tumors in mammography core biopsies. Suppression of UBE2C may be a potential therapy target in breast cancer. PMID: 24699941
24. the UBE2C gene is capable of promoting proliferation and invasion of lung cancer cells. Therefore, UBE2C may play a pivotal role in development and invasion of lung cancer. PMID: 24815438
25. Results suggest that UBE2C acts as an oncogene in prostate cancer progression. PMID: 24512726
26. Data suggest that ubiquitin conjugating enzyme UBE2C may serve as a potential therapeutic target aimed at inducing radiation and chemo sensitization. PMID: 24072565
27. Elevated levels of S100A8 and UBE2C were observed. PMID: 24114735
28. UBE2C positivity is independently associated with shorter cancer-specific survival in bladder cancer patients who underwent radical cystectomy. PMID: 23826418
29. Data indicate that expression-based risk indices of three genes UBE2C, TPX2, and MELK were more strongly associated with poor 5-year survival in adenocarcinoma patients. PMID: 23357462
30. High expression of UbcH10 was associated with pancreatic ductal adenocarcinoma. PMID: 23355337
31. the expression of cyclin D1, MCM7, TRIM29, and UBE2C was found to be significantly associated with progression to muscle-invasive bladder cancer. PMID: 23201130
32. UbcH10 overexpression has a critical role in lung carcinogenesis, and the evaluation of UbcH10 expression levels may be a new tool for the characterisation of non small cell lung carcinoma. PMID: 23102841
33. Data sugggest that UbcH10 may play an important role in non-small cell lung cancer (NSCLC) carcinogenesis, and silencing UbcH10 may represent a potential therapeutic strategy for NSCLC. PMID: 22760214
34. Overexpression of UbcH10 may be a useful indicator of endometrial carcinoma. PMID: 22415060
35. growth rate of SiHa and HeLa transfected with dominant negative-UBE2C was significantly reduced compared to vector control PMID: 22694363
36. High UBE2C mRNA expression was found to be of adverse prognostic significance in high-risk breast cancer patients PMID: 22056852
37. UbcH10 expression was associated with tumor invasion of the portal vein, tumor size, TNM staging, and tumor differentiation in hepatocellular carcinoma. PMID: 21354912
38. Effect of UBE2C overexpression on the proliferation of 293T cell line PMID: 21651863
39. Mediator complex subunit (MED)1 phosphorylation leads to UBE2C locus looping, UBE2C gene expression and cell growth in castration-resistant prostate cancer. PMID: 21556051
40. Spindle assembly checkpoint protein Cdc20 transcriptionally activates expression of ubiquitin carrier protein UbcH10. PMID: 21454660
41. Elevated expression of UbcH10 is associated with breast cancer. PMID: 19038004
42. elevated levels of Ubch10 and Cdc20 degrade cyclin B in hpv-16 iinfected cells, required for exit from mitosis, permitting initiation of the next round of DNA synthesis and cell cycle progression. PMID: 20739533
43. The unstructured N-terminal region of UbcH10 directly binds the 19 S regulatory complex of the 26 S proteasome, and it mediates the initiation of substrate translocation. PMID: 20007692
44. The overexpression of UbcH10 gene plays a critical role in the carcinogenesis and tumor progression of colorectal cancer. PMID: 19779934
45. show that UbcH10 overexpression leads to precocious degradation of cyclin B by the anaphase-promoting complex/cyclosome, supernumerary centrioles, lagging chromosomes, and aneuploidy. PMID: 20065091
46. Data imply that knocking-down UbcH10 protein expression may represent a potential therapeutic option for glioma. PMID: 19657671
47. UbcH10 is highly expressed in various human primary tumors and UbcH10 has an ability to promote cell growth and malignant transformation. PMID: 12874022
48. UbcH10 plays an important role in tumor development and that its inhibition in combination with agonists of the TRAIL receptor may provide an enhanced therapeutic index PMID: 15208666
49. UbcH10 overexpression is involved in thyroid cell proliferation and may represent a marker of thyroid anaplastic carcinomas PMID: 16106252
50. results showing aberrations in levels of gene expression and locus copy number of ubiquitin-conjugating enzyme E2C gene (UBE2C) suggest that this gene may play an important role in tumor progression leading to advanced colon cancer with liver metastasis PMID: 16772118

Show More

Hide All

HGNC: 15937

OMIM: 605574

KEGG: hsa:11065

STRING: 9606.ENSP00000348838

UniGene: Hs.93002